Jefferies Group LLC set a $40.00 price target on Axovant Sciences Ltd. (NYSE:AXON) in a research note released on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the company. Cowen and Company restated an outperform rating and set a $30.00 price objective on shares of Axovant Sciences in a research report on Wednesday, June 21st. BidaskClub upgraded Axovant Sciences from a sell rating to a hold rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered Axovant Sciences from a hold rating to a sell rating in a research report on Tuesday, July 11th. CIBC boosted their price objective on Axovant Sciences from $26.00 to $30.00 and gave the stock an outperform rating in a research report on Wednesday, June 14th. Finally, Oppenheimer Holdings, Inc. boosted their price objective on Axovant Sciences from $26.00 to $30.00 and gave the stock an outperform rating in a research report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $27.75.

Shares of Axovant Sciences (NYSE AXON) opened at 20.28 on Friday. The company’s market capitalization is $2.18 billion. The company’s 50 day moving average is $22.21 and its 200-day moving average is $19.71. Axovant Sciences has a 52 week low of $11.01 and a 52 week high of $26.49.

Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. On average, analysts expect that Axovant Sciences will post ($2.41) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Axovant Sciences Ltd. (AXON) Given a $40.00 Price Target at Jefferies Group LLC” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://theolympiareport.com/2017/08/29/axovant-sciences-ltd-axon-given-a-40-00-price-target-at-jefferies-group-llc.html.

Several large investors have recently added to or reduced their stakes in AXON. Norges Bank bought a new stake in Axovant Sciences during the fourth quarter worth approximately $508,000. Teachers Advisors LLC raised its stake in Axovant Sciences by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock worth $513,000 after buying an additional 2,038 shares during the period. Candriam Luxembourg S.C.A. raised its stake in Axovant Sciences by 77.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 160,000 shares of the biotechnology company’s stock worth $2,391,000 after buying an additional 70,000 shares during the period. Nationwide Fund Advisors raised its stake in Axovant Sciences by 70.9% in the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock worth $1,248,000 after buying an additional 34,654 shares during the period. Finally, Wells Fargo & Company MN raised its stake in Axovant Sciences by 34.3% in the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock worth $335,000 after buying an additional 5,733 shares during the period.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.